Your search matched 84 results
IBM Watson for Oncology | Blog
Originally built as a complement for a physician and not as a replacement, IBM Watson for Oncology launched a study to determine how closely the artificial intelligence computer and a panel of 12-15 multidisciplinary tumor board members could agree on treatment approaches.
On July 1st, The Centers for Medicare & Medicaid Services, through its Center for Medicare & Medicaid Innovation (CMMI), announced its newest voluntary oncology payment model, Enhancing Oncology Model (EOM).
Immuno-oncology is fundamentally changing what value means | In The Media
How will the pharma marketing, educational and service model adapt in response to redefined value in immuno-oncology?
Making the Most of Maturing Oncology Brands | In The Media
Our experts crafted a checklist for Pharmaceutical Executive that can be used to determine if there’s hidden vitality left in aging oncology brands and inspire outside-of-the-box, often low-investment solutions to grow the bottom line.
MDigitalLife (a division of the W20 Group) recently conducted an examination of specific cancer communities online.
As we’ve inched past the year mark of the pandemic, amidst the heartache of what has transpired and the fear of what is yet to come, there is an ironic undercurrent of collective chest-puffing—and rightly so.
Part I of a Syneos Health Series on New Oncology Commercialization Strategies
GENICOS | Agency
Full-service, oncology-focused advertising agency transforming products into brands and patients into survivors
Betting Big on Cancer.com | Blog
This month, Janssen launched Cancer.com, aiming to create an online destination for all things oncology.
GSW and Biosector 2 Are Shortlisted for 2019 MM&M Awards | In The Media
GSW and Biosector 2 are shortlisted for 2019 MM&M Awards for our client work with Endo Pharmaceuticals and Novartis Oncology.
In 2014, the American Society of Clinical Oncology (ASCO) released a landmark report about the state of cancer care in America.
There's been a spike in oncology DTC advertising in recent years, thanks to new drugs and mechanisms of action – and Syneos Health™ has the research to prove it.
PATIENT PARTNERS IN ONCOLOGY | Perspectives
Noticing important shifts in the rules of engagement between industry and patient advocates, Syneos Health Public Relations Group conducted in-depth interviews with dozens of patient organizations in early 2015.
Future look: The Impact of Biosimilars on Oncology | In The Media
Ben Curtis and Katherine Seay, inVentiv Health Managed Markets comment on how strategies will adjust with the advent of biosimilars.
Take a cursory look at the agenda for next month’s ASCO, and you’ll see oncology’s newest innovations—and promise—come with ever-increasing complexity of choices.
David Lennon, VP & Franchise Head for US Oncology at Novartis, showed the #efpphilly crowd where we’re at as an industry with technology and data and where our opportunities lie for greater collaboration.
Oncologists want to see themselves as enabling both patient and drug success.
More than 20 years ago, Gleevec ushered in a therapeutic revolution in oncology based on a relatively simple premise: If cancer cells are “addicted” to oncogenic mutations, targeting the troublesome protein might provide long-lasting disease control.
During this year’s Digital Pharma East conference, Stephanie Katzman, a healthcare strategist at LinkedIn, announced that the number of HCPs had grown from 3.5 million last year to over 5 million in the US alone and over 9 million globally in 2015.
CANCERCON is the experience that you never knew you needed because who the hell thinks about cancer when you’re not eighty years old?
Interested in how life science companies are approaching patient-centricity at eyeforpharma Barcelona 2020?
Suzanne Goss, Executive Vice President of Brand Strategy at Syneos Health Communications, shares her takeaways from the 2022 ASCO convention, and sheds light on the questions we need to ask ourselves as we move toward more equitable care.
Live from Cannes Lions: 9 people living with cancer + 6 months in their homes and lives = a story that shows it is possible to find a new normal
With lives dependent upon their decisions, oncologists are left to make treatment decisions for the betterment of their patients all while navigating a growingly crowded and complex landscape.
For many patients, receiving care right away is of vital importance.
2017 has marked a major shift in the way pharmaceutical giant Novartis will be using and expanding innovative digital platforms to share major congress experiences, education and medical information with physicians.
A daunting task for any doctor.
Shortages of critical cancer-fighting drugs have impacted 83% of U.S. oncologists in the past six months.* Around the world, doctors are negotiating availability, access and funding for the infusions they most want to prescribe.
It’s been mighty cold lately, hasn’t it?